Eisele Jeffrey 4
4 · Apellis Pharmaceuticals, Inc. · Filed Jan 18, 2024
Insider Transaction Report
Form 4
Eisele Jeffrey
Chief Development Officer
Transactions
- Sale
Common Stock
2024-01-17$65.58/sh−5,207$341,475→ 67,443 total
Footnotes (1)
- [F1]This is a scheduled sale from an established 10b5-1 plan.